Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for Spyre Therapeutics (SYRE) over the last 10 years, with Dec 2024 value amounting to $51.4 million.

  • Spyre Therapeutics' Shares Outstanding (Weighted Average) rose 18.92% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 18.92%. This contributed to the annual value of $51.4 million for FY2024, which is 1170.24% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Shares Outstanding (Weighted Average) of $51.4 million as of FY2024, which was up 1,170.24% from $4.0 million recorded in FY2023.
  • Spyre Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $51.4 million for FY2024, and its period low was $1.9 million during FY2020.
  • Over the past 3 years, Spyre Therapeutics' median Shares Outstanding (Weighted Average) value was $4.0 million (recorded in 2023), while the average stood at $19.3 million.
  • Data for Spyre Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 1,170.24% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Shares Outstanding (Weighted Average) stood at $1.9 million in 2020, then grew by 2.88% to $2.0 million in 2021, then increased by 24.72% to $2.5 million in 2022, then soared by 64.56% to $4.0 million in 2023, then skyrocketed by 1,170.24% to $51.4 million in 2024.